Acme United (ACU) Q2 2026 Earnings Beat Estimates on MyMedic Acquisition and Margin Expansion

• Acme United (ACU) reported Q2 2026 EPS of $1.22, significantly beating consensus estimates of $0.42 to $0.81 depending on the analyst source.
• Revenue surged 16% year-over-year to $62.72 million, driven largely by the acquisition of MyMedic, while organic growth stood at 8%.
• Gross margins expanded to 42.6% from 41.0% in the prior year period, reflecting improved operational efficiency and pricing power.
• The company anticipates continued margin recovery as tariff-related inventory costs normalize and lower-cost stock replaces higher-tariff stock through year-end.
• Key risks include elevated SG&A expenses at 32% of sales, potential tariff and freight cost fluctuations, and uneven geographic performance in Canada.",

"Acme United delivered robust second-quarter 2026 financial results that significantly exceeded Wall Street expectations. Earnings per share reached $1.22, surpassing analyst estimates that ranged from $0.42 to $0.81 across various financial media sources. This performance represents a substantial positive surprise, contrasting with the prior year's EPS of $1.16. The market reacted swiftly to the news, with shares surging approximately 11.92% following the release, moving near a 52-week high of $51.88.

Revenue totaled $62.72 million, beating forecasts of $58.08 million by nearly 8%. This top-line growth was bolstered by a 16% year-over-year increase in total sales. However, a significant portion of this growth was attributable to the acquisition of MyMedic. When excluding the impact of this acquisition, Acme United demonstrated a solid 8% organic growth rate.

The company operates through a diversified portfolio of brands including First Aid Only, PhysiciansCare, Westcott, and DMT. These brands supply cutting devices, measuring instruments, and safety products for school, home, office, and industrial sectors. The acquisition of MyMedic has added specialized safety products, such as hemostatic wound spray, to this mix, indicating an ongoing expansion in specialized safety product distribution.

How Did MyMedic Drive Growth and Margins?

The integration of MyMedic is a central theme in Acme United’s current strategy and financial performance. The acquisition has not only contributed to revenue growth but also provided opportunities for strategic expansion. Management is focused on expanding MyMedic’s distribution channels beyond its direct-to-consumer model into mass retail markets.

This strategic shift is expected to enhance the brand's visibility and accessibility to a broader customer base. The integration efforts are ongoing, with management highlighting the potential for MyMedic to become a significant contributor to future profitability.

In addition to revenue growth, the acquisition has supported margin expansion. Gross margins increased to 42.6% in Q2 2026, up from 41.0% in the prior year period. This improvement indicates enhanced operational efficiency and stronger pricing power within the company’s diversified product portfolio.

CEO Johnsen has outlined expectations for continued margin recovery throughout the remainder of the year. This trajectory is supported by the gradual easing of tariff pressures and the strategic replacement of higher-tariff inventory with lower-cost stock. The company anticipates strong Q4 profitability, supported by favorable seasonal demand patterns.

What Are the Key Risks and Financial Metrics?

Despite the strong performance, investors should monitor several key risks that could impact future results. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, which may weigh on net profitability if not managed effectively.

The company also faces potential headwinds from tariffs, freight costs, and currency volatility. These factors could disrupt supply chains and increase operational costs, particularly if global trade policies shift.

Geographic performance remains uneven, with Canada lagging behind other regions. This disparity highlights the need for targeted strategies to revitalize sales in underperforming markets.

Financially, Acme United maintains a conservative capital structure. The debt-to-equity ratio stands at 0.32x, and the interest coverage ratio is a robust 9.05x. The stock exhibits low volatility, indicated by a beta of 0.25x. Valuation metrics include a price-to-earnings ratio of 26.05x and a market capitalization of approximately $237.08 million. The company pays a dividend with a yield of 1.03%.

Looking ahead, Acme United is scheduled to release next earnings on October 20, 2026, with consensus EPS estimates set at $0.67. The stock's 52-week trading range has been between $35.50 and $64.17. Investors should watch for updates on the MyMedic integration and the company's ability to navigate tariff-related challenges.